Searching...
Searching...
8 results for “biotech”
Yeah. I think that it's gonna be pretty exciting. My prediction, my bold prediction is actually a pessimistic one on gene editing. I know everyone's excited about it, and Brian Armstrong is investing, and the Wall Street Journal's arguing about it. T
and this splitting off the people that want to and won't want to, the ones that can and cannot. I assume it's gonna really be the ones that want to and not want to because eventually, this sort of technology is gonna become really cheap. Yeah. So I t
on biotech, mostly via protein design. It's starting to impact cellular systems, cell therapies for example, GC therapeutics and AI. I think the even though it's framed in terms of large language models, I think its impact on language is less, I mean
...on on biotech, mostly via protein design. It's starting to impact cellular systems, cell therapies for example, GC therapeutics and AI.
getting embryos from stem cells. For example, embryos from stem cells, couples that can't you know, you probably know a lot of people like this. People who would get to a point, either they had a fertility problem when they were young or they get to
...that in biotech, we're in this sort of moment where there's a lot of opportunity in in rebundling. The types of platforms that I see that I'm super excited about are this composite of, incredible synthetic biology and genomics tools,
...biotech if there are hyperscalers that emerge. There's this question. There there's a lot of AI and biology companies that are raising a lot of capital, and some just have no aims to make drugs.
biological weapons, chemical weapons conventions, and explosives conventions and stuff out there and just, like, the things that they describe and the things that are possible. And, like, if you ask a lot of virologists, you know, like, not it's very
Have a podcast?
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.